Related Experiment Video
Updated: Dec 28, 2025
07:27
Recurrent Herpetic Stromal Keratitis in Mice, a Model for Studying Human HSK
Published on: December 18, 2012
12.3K
Immunomodulatory Strategies in Herpes Simplex Virus Encephalitis
1Research Center in Infectious Diseases, CHU de Quebec-Laval University, Quebec City, Canada.
Clinical Microbiology Reviews
|February 14, 2020
Summary
New treatments are needed for Herpes Simplex Virus 1 (HSV-1) encephalitis (HSE). Immunomodulatory agents, timed with inflammation biomarkers, may improve outcomes for this severe brain infection.
Area of Science:
- Neuroscience
- Virology
- Immunology
Background:
- Herpes simplex virus 1 (HSV-1) causes life-threatening HSV encephalitis (HSE).
- Untreated HSE mortality is 70%, with survivors often experiencing permanent neurological deficits.
- Current treatments reduce mortality but neurological recovery remains incomplete for most.
Purpose of the Study:
- To review recent therapeutic advancements for improving clinical outcomes in HSE.
- To emphasize the potential of immunomodulatory agents as adjunctive therapies.
- To highlight the need for precise timing and biomarker identification for immunomodulation.
Main Methods:
- Review of current literature on HSV encephalitis treatments.
- Analysis of therapeutic targets including viral replication and inflammatory responses.
- Discussion of immunomodulatory strategies and their optimal application.
Main Results:
- Cerebral damage in HSE results from both viral replication and excessive inflammation.
- Adjunctive immunomodulatory therapy shows promise for ameliorating HSE outcomes.
- Optimal therapeutic window for immunomodulators requires identification of inflammation biomarkers.
Conclusions:
- There is an urgent need for novel therapies beyond antiviral treatment for HSE.
- Immunomodulatory agents represent a promising avenue for improving neurological recovery.
- Targeting the inflammatory response, guided by biomarkers, is crucial for effective HSE management.
